Massimo Catarini
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
-
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
- Hematology 21
- Multiple Myeloma Research and Treatments 18
-
- Protein Degradation and Inhibitors 11
- Cancer therapeutics and mechanisms 2
- Histone Deacetylase Inhibitors Research 2
- Co-authors
- Laura Corvatta (20 shared papers)Massimo Offidani (21 shared papers)Francesco Alesiani (18 shared papers)Marino Brunori (17 shared papers)Pietro Leoni (20 shared papers)Giuseppe Visani (14 shared papers)Attilio Olivieri (7 shared papers)Riccardo Centurioni (14 shared papers)
In The Last Decade
Massimo Catarini
29 papers receiving 457 citations
Peers
Comparison fields: 5 of 56
- Hematology 298
- Oncology 230
- Geriatrics and Gerontology 25
- Genetics 57
- Pathology and Forensic Medicine 71
Countries citing papers authored by Massimo Catarini
This map shows the geographic impact of Massimo Catarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Catarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Catarini more than expected).
Fields of papers citing papers by Massimo Catarini
This network shows the impact of papers produced by Massimo Catarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Catarini. The network helps show where Massimo Catarini may publish in the future.
Co-authors
The 25 scholars most cited alongside Massimo Catarini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. | 2006 | 62 |
| 2 | 2012 | 47 | |
| 3 | 2012 | 41 | |
| 4 | 2012 | 36 | |
| 5 | 2008 | 34 | |
| 6 | 2004 | 34 | |
| 7 | 2007 | 25 | |
| 8 | 2008 | 23 | |
| 9 | 2004 | 21 | |
| 10 | 2011 | 17 | |
| 11 | 2016 | 17 | |
| 12 | 2014 | 16 | |
| 13 | 2011 | 14 | |
| 14 | 2004 | 13 | |
| 15 | 2013 | 13 | |
| 16 | 2010 | 12 | |
| 17 | 2008 | 9 | |
| 18 | 2013 | 6 | |
| 19 | 2010 | 5 | |
| 20 | 2010 | 4 |
About Massimo Catarini
Massimo Catarini is a scholar working on Hematology, Molecular Biology, Oncology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 30 papers that have together received 465 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (18 papers), Protein Degradation and Inhibitors (11 papers), Peptidase Inhibition and Analysis (8 papers), Cancer Treatment and Pharmacology (8 papers), Lymphoma Diagnosis and Treatment (4 papers), Cancer therapeutics and mechanisms (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Histone Deacetylase Inhibitors Research (2 papers). The work is most often cited by research in Hematology (298 citations), Oncology (230 citations), Geriatrics and Gerontology (25 citations), Genetics (57 citations) and Pathology and Forensic Medicine (71 citations). Massimo Catarini has collaborated with scholars based in Italy, Brazil and Poland. Frequent co-authors include Laura Corvatta, Massimo Offidani, Francesco Alesiani, Marino Brunori, Pietro Leoni, Giuseppe Visani, Attilio Olivieri, Riccardo Centurioni, Mauro Montanari and Anna Mele. Their work appears in journals such as Blood, European Journal Of Haematology, British Journal of Haematology, Journal of Palliative Medicine and The Hematology Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.